Topic
7 recent stories.
Policy / European Union
The European Medicines Agency has issued a positive opinion on the Dengue Tetravalent Vaccine (Live, Attenuated) created by Takeda for use outside the EU, highlighting its effectiveness in preventing severe dengue disease in children and adolescents.
08 May 2026
Policy / European Union
Strimvelis, an innovative gene therapy for treating severe combined immunodeficiency due to adenosine deaminase deficiency (ADA-SCID), has been approved for use in the EU, offering hope to patients without suitable bone marrow donors.
08 May 2026
Policy / European Union
Pregabalin Viatris, a generic form of the widely used medication Lyrica, has been formally recognised by the European Medicines Agency for its efficacy in treating neuropathic pain and anxiety disorders in adults.
08 May 2026
Society / European Union
The European Medicines Agency has granted marketing authorisation for Atazanavir Viatris, a new generic HIV treatment that promises to be an effective option for patients aged 6 and over, particularly alongside low-dose ritonavir.
07 May 2026
Policy / European Union
The European Medicines Agency (EMA) has reaffirmed the approval of CellCept, a vital immunosuppressant used to prevent organ rejection in transplant patients, seen as more effective than alternatives.
07 May 2026
Policy / European Union
Uplizna (inebilizumab), effective for reducing NMOSD and IgG4-related disease symptoms, has gained conditional approval in the EU. Key usage protocols and safety guidelines are outlined for healthcare providers.
07 May 2026
Policy / European Union
Dovprela, an antibiotic for multidrug-resistant tuberculosis, has received standard authorisation from the European Medicines Agency, moving beyond its initial conditional approval.
07 May 2026